Follow-up study for babies in a NICU antibiotic trial
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study follows families and newborn babies who already joined the main NANO trial. It checks health and outcomes after NICU antibiotic treatment, which may help improve future care for very premature babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already agreed to and enrolled in the main NANO (parent) trial
- Your baby must be part of the NANO study site where follow-up is offered
- Your baby must have been born at 23.0 to 30.6 weeks of pregnancy (very premature)
- Your baby must be an inborn baby at the study site (not transferred from another hospital)
- The main trial excluded babies considered very low risk, very high risk, or too sick to survive; your baby would not have been enrolled if those applied
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how involving family members in the care of premature babies in the NICU might improve the baby's quality of life. If you are a parent of a premature baby who has been in the NICU for at least a week, you may be able to join.
This study tests whether giving special beneficial bacteria (probiotics) to premature babies who received antibiotics in the hospital can help their brain and nervous system develop better. Researchers will follow your baby for 6 months to see if probiotics improve development.
This trial tests a “family-centered” approach that aims to keep mothers closely involved with their babies in intensive newborn care, rather than separating them. It may help families by supporting safer, more continuous mother–baby bonding during treatment.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
This trial compares two approaches for premature babies born at 26 to 34 weeks who have risk factors for early infection: giving antibiotics only if they develop signs of infection versus giving them right away. It aims to find out if waiting is safe and reduces unnecessary antibiotic use.
This study tests whether giving a probiotic (a 'good' bacteria) to babies who received antibiotics shortly after birth can help their developing gut and immune system. Participants will receive a daily probiotic or placebo for about 6 weeks, and their health will be monitored.
Hear when a new Premature Birth trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.